Evidence map›Paper›PMID 26260214›Full record

ArticleNeurobiology of aging2015

Variation in PARK10 is not associated with risk and age at onset of Parkinson's disease in large clinical cohorts.

Javier Simón-Sánchez, Peter Heutink, Thomas Gasser, International Parkinson's Disease Genomics Consortium (IPDGC)

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of aging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Javier Simón-SánchezGenetics and Epigenetics of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; Genetics and Epigenetics of Neurodegeneration, German Center for Neurodegenerative diseases (DZNE)-Tübingen, Tübingen, Germany. Electronic address: javier.simon-sanchez@dzne.de.
Peter HeutinkDepartment of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; Genome Biology of Neurodegenerative Diseases, German Center for Neurodegenerative diseases (DZNE)-Tübingen, Tübingen, Germany.
Thomas GasserDepartment of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; Genome Biology of Neurodegenerative Diseases, German Center for Neurodegenerative diseases (DZNE)-Tübingen, Tübingen, Germany.
International Parkinson's Disease Genomics Consortium (IPDGC)
University of Tübingen · DEHertie Institute for Clinical Brain Research · DE

Funding

Intramural NIH HHS Z99 AG999999
6 · The paper itself

Abstract

A recent study in autopsy-confirmed Parkinson's disease (PD) patients and controls revived the debate about the role of PARK10 in this disorder. In an attempt to replicate these results and further understand the role of this locus in the risk and age at onset of PD, we decided to explore NeuroX genotyping and whole exome sequencing data from 2 large independent cohorts of clinical patients and controls from the International Parkinson's Disease Genomic Consortium. A series of single-variant and gene-based aggregation (sequence kernel association test and combined multivariate and collapsing test) statistical tests suggested that common and rare genetic variation in this locus do not influence the risk or age at onset of clinical PD.

Indexed as

Genetic Association StudiesAdultAgedAge of OnsetCohort StudiesExomeFemaleGenetic VariationGenotyping TechniquesHumansMaleMiddle AgedParkinson DiseaseRiskSequence Analysis, DNANeurogeneticsNeuroXPARK10Parkinson's diseaseWhole exome sequencing

Identifiers

PMID26260214
PMCPMC8978882
OpenAlexW2117480586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.